INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
12 Febrero 2024 - 8:00AM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company targeting
microglial activation and neuroinflammation as a cause of
Alzheimer’s disease (AD) with
XProTM (XPro1595; pegipanermin), a dominant-negative
inhibitor of soluble TNF, announced today that RJ Tesi, M.D., Chief
Executive Officer, and David Moss, Chief Financial Officer, will
present a corporate update at the Oppenheimer 34th Annual
Healthcare Life Sciences Conference being held virtually from
February 13-14, 2024.
Presentation
Date:
Wednesday, February 14, 2024
Time:
11:20am –
11:50am ET
Webcast
Link:
https://wsw.com/webcast/oppenheimer33/inmb/2759756
Dr. Tesi and Mr. Moss will be available for one-on-one meetings
throughout the conference. Please contact your Oppenheimer
salesperson to schedule one-on-one meetings with the management
team.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on
developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in
clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. XPro™, first
of several DN-TNF products, is in clinical trials to determine if
it can treat patients with Early Alzheimer’s disease. The Natural
Killer Cell Priming Platform includes INKmune™, a therapy developed
to prime a patient’s NK cells to treat patients with cancer.
INKmune™ uses a precision medicine approach for the treatment of a
wide variety of hematologic and solid tumor malignancies. The
INKmune™ trial is enrolling patients into a US Phase I/II trial in
men with metastatic castrate resistant prostate cancer and into a
Phase I program in MDS/AML in Europe. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720 info@inmunenbio.com
Investor Contact: Jason Nelson, Core IR (516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025
INmune Bio (NASDAQ:INMB)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025